Future of Radiosensitivity Testing
Author Information
Author(s): E. Anderson, C.F. Arlett, A. Barrett, S. Bentzen, W.A. Brock, N. Burnet, J. Cole, S.E. Davidson, J.O.T. Deeley, S.A.G. Elyan, A. Galpine, N.E. Gentner, M.N. Gould, D.G. Harnden, J.H. Hendry, A. Horwich, R.D. Hunter, R.D. James, M.C. Joiner, P.A. Lawton, J.B. Little, N.J. McNally, E.P. Malaise, J.V. Moore, N. Nakamura, C.J. Roberts, E.K. Rofstad, G.M. Ross, D. Scott, G.G. Steel, C. Streffer, H.D. Suit, G.M. Taylor, J. Thacker, H.D. Thames, I. Turesson, P.R. Twentyman, I. Vorechovsky, C.M.L. West, M. Wilson
Primary Institution: Cancer Research Campaign Paterson Institute for Cancer Research
Hypothesis
Can radiosensitivity testing improve radiotherapy outcomes?
Conclusion
There are measurable differences in radiosensitivity among tumors, but more research is needed to develop reliable testing methods.
Supporting Evidence
- Radiosensitivity varies among different tumor types.
- Some patients experience severe damage from radiation despite normal treatment.
- Studies show significant differences in radiosensitivity within tumor classes.
- Normal individuals also show variability in radiosensitivity.
- New assays are being developed to improve testing accuracy.
Takeaway
Some people are more sensitive to radiation than others, and figuring this out could help doctors treat cancer better.
Methodology
Various assays were used to measure radiosensitivity in tumor and normal cells, including the cell adhesive matrix assay and clonogenic assays.
Potential Biases
Potential biases in individual cell type responses may not represent overall radiosensitivity.
Limitations
Current tests are slow and expensive, and there is no simple routine test for the general population.
Participant Demographics
Participants included researchers and clinicians from various institutions, with a focus on cancer research.
Statistical Information
P-Value
0.05
Statistical Significance
p=0.05
Want to read the original?
Access the complete publication on the publisher's website